Connect with us

Hi, what are you looking for?

Monday, Mar 4, 2024
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Awakn Life Sciences helps establish psychedelics clinics in Portugal

Awakn will also be providing its clinical protocols and training to Portuguese clinicians in a 10-year agreement

Awakn Life Sciences provides its protocols and training to Portuguese clinicians
Awakn's chief research officer and head of ketamine therapy speak at the PSYCH Symposium psychedelics conference last year. London, U.K. Photo via Awakn Life Sciences

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) has signed an agreement with an anonymous entity in Portugal to help establish a series of psychedelics clinics there. Awakn will also be providing that party with a license for its clinical protocols and training.

The United Kingdom-based company announced the new agreement on Tuesday and will support the unnamed Portuguese healthcare consortium currently operating in “stealth-mode” to establish the new facilities, the first of which will be situated in Lisbon.

This will be the first licensing partnership Awakn has entered into in Europe.

Read more: Lucy Scientific Discovery applies for Health Canada approval to produce cocaine and heroin

Read more: Numinus expands psychedelics research operations in Arizona

Awakn’s clinical protocols are used for the treatment of alcohol use disorder, eating disorders, PTSD and depression. The company will be providing the Portuguese partner with a license to those protocols for 10 years and will also be training its clinicians on how to properly utilize them.

Awakn specializes in treating mental health and addiction disorders through psychedelic-assisted therapy with ketamine and MDMA. In December, Awakn received a $2.5 million grant from United Kingdom health authorities for a large-scale clinical trial studying the efficacy of ketamine for the treatment of alcohol use disorder.

According to Awakn, Portugal has a high rate of mental health conditions within its population. Somewhere between 20-30 per cent of its citizens have faced challenges with mental health in their lifetime.

Read more: Psyched Wellness formulates first commercial Amanita muscaria extract

Read more: Awakn set to research ketamine for alcohol use disorder

Possession of all drugs for personal use has been decriminalized in Portugal since 2001, but the sale or distribution of significant quantities of substances like MDMA, ketamine or psilocybin remains illegal unless authorized by health authorities in the country.

“Law 30/2000, adopted in November 2000 but in place since July 2001, decriminalized consumption, acquisition and possession of drugs for personal consumption,” says the European Monitoring Centre for Drugs and Drug addiction in reference to narcotic drugs and psychoactive substances in Portugal.

In September last year, Toronto’s Psyence Group Inc. (CSE: PSYG) (OTCQB: PSYGF) was able to export psilocybin mushrooms to its research partner in the country Psilo Pharma, but had to obtain stringent permissions from Portuguese regulators to do so.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Rowan Dunne on Twitter




Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AI and Autonomy

The act uses a risk-based approach, prioritizing high-risk areas such as government use of AI for biometric surveillance


German officials who met with the Argentinian delegation will be travelling to South America next month to further strengthen ties


Amended nonbinding deal reached with Somai Pharmaceuticals for RPK Biopharma Unipessoal


European demand continued to plummet with a year-on-year decrease of 59 per cent